Dosing of zoledronic acid with its anti-tumor effects in breast cancer.
Dosing of zoledronic acid with its anti-tumor effects in breast cancer.
复制标题
唑来膦酸的剂量及其在乳腺癌中的抗肿瘤作用。
DOI：
10.1016/j.jbo.2015.08.001
复制
发表时间：
2015-09
影响因子：
3.4
通讯作者：
Hu X
中科院分区：
文献类型：
--
作者：
Zhao X;Hu X
双膦酸盐在乳腺癌的治疗中发挥了重要作用，主要是在骨转移患者中，通过降低骨折、脊髓压迫和高钙血症的风险。唑来膦酸是最常用的静脉给药药物，传统上按每月给药方案给药。临床前研究表明，唑来膦酸可以抑制肿瘤细胞的血管生成、侵袭和粘附。唑来膦酸治疗的不同时间和方案的几项临床研究已经证明了其抗肿瘤作用，以及其对骨健康的保护作用，在绝经后妇女辅助乳腺癌治疗。一般来说，早期开始唑来膦酸治疗，同时辅助治疗，已被发现是最有益的。然而，关于唑来膦酸最有效的治疗方案和相对效力的问题仍然存在。因此，我们回顾了现有的临床研究，以检查唑来膦酸治疗剂量对乳腺癌患者临床结局的影响。
Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia. Zoledronic acid, the most frequently used intravenous agent, has been traditionally administered on a monthly dosing schedule. Preclinical studies have demonstrated that zoledronic acid can inhibit angiogenesis, invasion, and adhesion of tumor cells. Several clinical studies of different timings and schedules of zoledronic acid therapy have demonstrated its anti-tumor effects, as well as its protective effect on bone health, in postmenopausal women during adjuvant breast cancer therapy. In general, early initiation of zoledronic acid, concomitantly with adjuvant therapy, has been found to be most beneficial. However, questions remain over the most effective schedule of treatment and relative potency of zoledronic acid. Therefore, we review the existing clinical studies to examine the influence of dosing of zoledronic acid therapy on clinical outcomes in patients with breast cancer.